nothing new IMHO
Nyrada is in the early and crucial stages of development, where the risk is higher and the future potential depends on the success of their clinical trials.
Loss - operating loss of AU$2.46 million, which is typical for early stage biotech
first dosing expected before the end of March 2025
nothing exciting
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $69.60M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.3¢ | 32.5¢ | $195.9K | 589.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14970 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 20100 | 1 |
View Market Depth
| Last trade - 15.29pm 25/07/2025 (20 minute delay) ? |
| NYR (ASX) Chart |